BioStar Ventures is a venture capital partnership created by some of the most successful and innovative physician thought leaders coupled with decades of venture capital experience and health care executives. The group has unique proprietary deal-flow, knowledge of new devices and protocols, insight and knowledge into the FDA, clinical and bench research and finally the acquisition needs and in house development of the major strategic acquirers. BioStar Ventures’ capital efficient model is a unique marriage of world renowned clinicians with experienced venture capitalists. This allows BioStar Ventures to capture unique deal flow and leverage decades of scientific knowledge, clinical expertise, and patient care delivery experience in early stage medical devices to BioStar’s investors and limited partners.
BioStar Ventures invests in companies where we can leverage the clinical expertise of the BioStar Ventures Team. Our key focus is in cardiovascular, orthopedic, and neuroscience areas which accounts for approximately two thirds of all medical device areas. Often a BioStar Ventures medical venture partner or advisor will serve on the SAB of our portfolio companies as we believe our clinical expertise can only expedite a company’s success in device development and knowledge regarding acquisition targets and strategy.
If appropriate, BioStar Ventures does not hesitate to serve as an investor but follow-on invests as well. Our initial investment in a company ranges from $250K - $3 million, depending upon the technology and stage of a company’s development. We intend to support our portfolio companies in their follow-on financing rounds through time of exit. Accordingly, BioStar Ventures invests between $2 - $6 million over the life of an investment. Strategic and institutional investors to date have included the DOW Foundation, Boston Scientific, Synthes and Morgan Stanley’s Front-Point Funds.